Open AccessCurrent Clinical Indications for Plerixafor
Author(s) -
Stefan Früehauf
Publication year - 2013
Publication title -
transfusion medicine and hemotherapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.971
H-Index - 39
eISSN - 1660-3818
pISSN - 1660-3796
DOI - 10.1159/000354229
Subject(s) - plerixafor , medicine , cxcr4 , multiple myeloma , clinical trial , transplantation , cxcr4 antagonist , hematopoietic stem cell transplantation , lymphoma , oncology , stromal cell , pharmacology , chemokine , receptor
Autologous and allogeneic hematopoietic stem cell (HSC) transplantation are considered the standard of care for many malignancies including lymphoma, multiple myeloma, and some leukemias. In many cases, mobilized peripheral blood has become the preferred source for HSCs. Plerixafor, an inhibitor of the interaction between CX chemokine receptor 4 (CXCR4) and stromal derived factor-1 alpha (SDF-1), has been evaluated in clinical trials and approved by the FDA and EMA. This agent has very modest toxicity and appears to be quite potent at HSC mobilization. Current clinical indications for the use of plerixafor are the subject of this review.